Compare Global X FTSE Southeast Asia ETF (ASEA) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X FTSE Southeast Asia ETF vs Neurocrine Biosciences Inc — how do they compare? Global X FTSE Southeast Asia ETF trades at $21.47, while Neurocrine Biosciences Inc trades at $152.5 (market cap $16.46B). The key difference: Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ASEA | NBIX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $21.53 | $185.50 |
52-Week Low | $16.86 | $123.10 |
Market Cap | — | $16.46B |
Enterprise Value | — | $16.48B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X FTSE Southeast Asia ETF
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
